Adam M. Burgoyne, MD, PhD, discusses updated findings from the CARES-310 trial and future considerations for unresectable HCC management.
Adam M. Burgoyne, MD, PhD
Advertisement
Articles by Adam M. Burgoyne, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5